Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

Investors may react cautiously to news that J. B. Chemicals & Pharmaceuticals Limited's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 3.041000
forwardPE 27.119757
debtToEquity 0.812000
earningsGrowth 0.137000
revenueGrowth 0.102000
grossMargins 0.663970
operatingMargins 0.189580
trailingEps 41.630000
forwardEps 0.000000

JBCHEPHARM's current ratio of 3.041, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as JBCHEPHARM has enough cash and current assets to handle its immediate liabilities comfortably.
JBCHEPHARM's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
With positive earnings and revenue growth, J. B. Chemicals & Pharmaceuticals Limited is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

JBCHEPHARM's price projections have gradually decreased, indicating a more conservative outlook from analysts. The repeated downward revisions suggest waning confidence in the company's ability to achieve its previous targets.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


In recent market activity, 57 sales of JBCHEPHARM shares took place, with market price at 1765.3482494688872.There were no sell transactions during the given period.The trend of more buys compared to sells around J. B. Chemicals & Pharmaceuticals Limited's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


Analysts have shown a buy bias for JBCHEPHARM, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to JBCHEPHARM, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.